Reports Q1 revenue C$88.75M vs. C$75.78M last year. The company said, “We delivered strong top line growth in the first quarter of fiscal 2026, led by momentum in our Canada adult-use cannabis business where we’re gaining share in high-demand categories, and steady performance across our global medical cannabis business. This reflects the early impact of our focused commercial strategy and a more disciplined execution. I’m confident we can continue to build on this momentum through the remainder of the year.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGC:
- Canopy Growth Appoints Margaret Shan Atkins to Board
- Options Volatility and Implied Earnings Moves Today, August 08, 2025
- CGC Upcoming Earnings Report: What to Expect?
- Canopy Growth Expands 7ACRES Brand to Australia
- Options Volatility and Implied Earnings Moves This Week, August 04 – August 08, 2025